3:30pm Chair Introduction

Bruce Levine, Professor, Cancer Gene Therapy, University of Pennsylvania

3:35pm Presentation: Evolution, Revolution: How Adaptimmune is Developing the Next Generation of TCR T-Cell Therapies Against Solid Tumors

• Exploring Adaptimmune’s MAGE A4 franchise from the first gen product Afamicel on a path commercialisation to the next gen product ADP-A2M4CD8 increasing signals across multiple indications
• How clinical and translational learnings feed from one to the other and influence trial design

Joanne Brewer, Chief Scientific Officer, AdaptImmune

3:50pm Presentation: The Practicalities and Pitfalls of Orchestrating Autologous Therapies

• An insight into first hand case studies, focusing directly on orchestration implementation
• A deep dive into the best practice of orchestrating Autologous therapies, and what to avoid during implementation

Matthew Lakelin, Vice President, Scientific Affairs, Product Development & Co-Founder, TrakCel

4:05pm Presentation: Pushing the Design Envelope in Autologous T Cell Therapies

• Improvements in autologous cell therapies through potency enhancers
• Shortened ex vivo culture enhances potency in pre-clinical models and clinical data
• Future vision of the ultimate autologous off the shelf cell therapy via in vivo gene delivery

Bruce Levine, Professor, Cancer Gene Therapy, University of Pennsylvania

4:20pm Presentation: Novel Targets for Autologous CAR-T Therapies in Solid Tumors

• To date, autologous cell therapies have not demonstrated clear or broad clinical success in solid tumors
• Effective solid tumor targeting with autologous CAR-T therapies demands actionable targets, active constructs and smart clinical approaches

Jason Litten, Chief Medical Officer, Chimeric Therapeutics

4:35pm  Session Panel & Q&A

With all session participants